Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Sep 6, 2019 (7 years ago)

Gatifloxacin Ophthalmic Solution 0.5%

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications:OOS for unknown impurity.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Gatifloxacin Ophthalmic Solution 0.5%, 2.5 mL per bottle, Rx Only, Mfd. for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505. Made in India. NDC: 0378-5431-35

Affected NDC 0378-5431-35

Compare with the code on your package — it is the most precise check available.

Drug: Gatifloxacin Category: Eye Drops & Ophthalmic

Recalling firm
Mylan Pharmaceuticals Inc.
Origin
WV, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1848-2019 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Gatifloxacin recalls

See all
Class II · Moderate risk

Pred Acetate / Gatifloxacin 1% / 0.5% Susp

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0051-2023
Class III · Low risk

Gatifloxacin Ophthalmic Solution

Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.

Terminated Stability / shelf life Lupin Pharmaceuticals Inc. NDC 68180-435-01 D-0326-2022
Class III · Low risk

Gatifloxacin Ophthalmic Solution

Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.

Terminated Stability / shelf life Lupin Pharmaceuticals Inc. NDC 68180-435-01 D-0091-2022

Other recalls by Mylan Pharmaceuticals Inc.

All 2019 recalls
Class II · Moderate risk

Prasugrel Tablets

Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria

Ongoing Dissolution failure Mylan Pharmaceuticals Inc NDC 0378-5186-93 D-0839-2026